$17.37
-0.40-2.25%
Last update: Nov 13, 12:55 PM
Arcus Biosciences Inc
RCUSNYSE
Arcus Biosciences fell 10.2% from $19.79 to $17.77, behind the S&P 500's +12.7%. Its worst day was Oct 21 (−19.6%), and its low came Nov 5 at $17.69.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Arcus Biosciences shares fell 14.4%, while the S&P 500 fell 1.1%.
−14.4% · S&P 500 −1.1%
Arcus Biosciences shares fell 11.3%, while the S&P 500 rose 0.3%.
Story events cover the past 12 months · Times ET
−11.3% · S&P 500 +0.3%
EPS of $-0.89 beat the $-1.09 estimate on $33.0M revenue (est. $25.0M).
−3.6% · S&P 500 −0.6%
EPS of $-1.02 missed the $-0.85 estimate on $17.0M revenue (est. $26.4M).
−0.2% · S&P 500 +1.4%
Arcus Biosciences shares rose 12.0%, while the S&P 500 fell 0.3%.
+12.0% · S&P 500 −0.3%
EPS of $-0.72 beat the $-0.85 estimate on $41.0M revenue (est. $21.6M).
+2.3% · S&P 500 −0.2%
Arcus Biosciences closed at its highest level of the year, 59.5% above where the year started.
+4.8% · S&P 500 +0.3%
Arcus Biosciences shares fell 19.6%, while the S&P 500 rose 0.5%.
−19.6%, the year's worst day · S&P 500 +0.5%
EPS of $-1.00 missed the $-0.90 estimate on $9.0M revenue (est. $9.0M).
−8.4% · S&P 500 −4.4%
Where it ended: a close of $17.77 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $-0.86, revenue est. $6.4M).
Nothing in the past 12 months.
All RCUS dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RCUS and SPY from Benzinga historical bars. Not investment advice.
